NewcelX Ltd. Ordinary Shares (NCEL)
Stock · NASDAQ · Health Care
$2.5as of 10/16/2026
Price chart
Active signals
NCEL Signal Track Record
How signals performed across all stocks →What NCEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 24 | -15.4% | 33% | July 1, 2026 |
| Volume Spike | 20 | -17.4% | 35% | July 1, 2026 |
| Bollinger Band BreakdownActive now | 18 | -4.6% | 33% | September 21, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -10.5% | 17% | September 30, 2026 |
| Any 20-session window (baseline) | -6.1% | 36% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NCEL
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 9
- Website
- nlspharma.com/
Fundamentals
- 1-day range
- $2.61$2.9
- Market cap
- $17.98M
- P/E (trailing)
- —
- P/E (forward)
- -4.75
- EPS (trailing)
- $-1.33
- Dividend yield
- —
- Beta
- 1.04
- Avg. volume
- 8.5K
Forecasts
1 analyst ratings
NewcelX Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- NCELNewcelX Ltd. Ordinary Shares$2.5▼ 12.28%Market cap $17.98MP/E —$1.83$18.4
- CTXRCitius Pharmaceuticals Inc. Common Stock$0.46▲ 0.00%Market cap $17.62MP/E —$0.46$2.19
- LPCNLipocine Inc. Common Stock$1.56▼ 7.14%Market cap $17.56MP/E —$1.59$12.37
- MRKRMarker Therapeutics Inc. Common Stock$1.04▲ 13.04%Market cap $18.67MP/E —$0.84$2.46
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- NRSNNeuroSense Therapeutics Ltd. Ordinary Shares$3.07▼ 3.15%Market cap $19.00MP/E —$3.05$26.64
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NCEL NewcelX Ltd. Ordinary Shares | $17.98M | — | $2.5 | ▼ 12.28% | $1.83$18.4 |
| CTXR Citius Pharmaceuticals Inc. Common Stock | $17.62M | — | $0.46 | ▲ 0.00% | $0.46$2.19 |
| LPCN Lipocine Inc. Common Stock | $17.56M | — | $1.56 | ▼ 7.14% | $1.59$12.37 |
| MRKR Marker Therapeutics Inc. Common Stock | $18.67M | — | $1.04 | ▲ 13.04% | $0.84$2.46 |
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| NRSN NeuroSense Therapeutics Ltd. Ordinary Shares | $19.00M | — | $3.07 | ▼ 3.15% | $3.05$26.64 |
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Olivier Samuel · April 27, 2026 · Buy114.5K
- Olivier Samuel · April 27, 2026 · Buy81.8K @ $2.75
- Michel Revel · April 27, 2026 · Buy76.4K
- Michel Revel · April 27, 2026 · Buy54.5K @ $2.75
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
NewCelX Management to Attend Breakthrough T1D Congress
NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.
NewCelX Management to Attend Breakthrough T1D Congress. NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.